Condition
Malignant Neoplasm of Large Intestine
Total Trials
4
Recruiting
0
Active
0
Completed
3
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
Termination Rate
0.0%
0 terminated out of 4 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
50%
2 trials in Phase 3/4
Results Transparency
33%
1 of 3 completed with results
Key Signals
1 with results100% success
Data Visualizations
Phase Distribution
4Total
Not Applicable (1)
P 1 (1)
P 3 (2)
Trial Status
Completed3
Unknown1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT04534075Phase 3Completed
Dietary Fiber During Radiotherapy - a Placebo-controlled Randomized Trial
NCT01420874Phase 1Completed
Anti-CD3 x Anti-Erbitux® Armed Activated T Cells (Phase Ib) for Gastrointestinal (GI Cancer)
NCT02363049Phase 3UnknownPrimary
Colectomy in Patients With Asymptomatic and Unresectable Stage IV Colon Cancer
NCT01385579Not ApplicableCompletedPrimary
Effectiveness of Direct-to-Patient Outreach on Colorectal Cancer Screening Within a Low Income and Diverse Population
Showing all 4 trials